Development and Persistence of Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients in Comparison With Immunocompetent Patients
Sponsor study identifier
observational
300
1 country
2
Study Start
May 29, 2020
Actual (reported)Primary Completion
May 29, 2020
Actual (reported)Study Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 29, 2020
Actual (reported)May 29, 2020
Actual (reported)May 29, 2020
Actual (reported)June 1, 2020
Actual (reported)June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Incidence of IgG against SARS-CoV-2
Proportion, Rate
one year
titration and evolution of humoral response (IgG) along first 12 months after having Covid-19
12 months
Reinfection of Covid-19
one year
Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
Report of clinical data
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Liver transplant and control patients (propensity score including age, sex, and severity of previous covid19 episode)
Victor Fernandez Alonso
Madrid, 28009, Spain
Victor Fernández Alonso
Madrid, 28009, Spain
Serum
Magdalena Salcedo, MD PhD
Liver Transplantation Unit
First Submitted
May 29, 2020
First Posted
June 1, 2020
Study Start
May 29, 2020
Actual (reported)Primary Completion
May 29, 2020
Actual (reported)Mortality
12 months after Covid-19
Contact the study team to confirm eligibility.
Study Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 2, 2020
Record last verified: 2020-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: